Form 4: Castle Biosciences CCO Acquires Shares Post-Vesting

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, acquired 9,207 shares of common stock and 9,207 performance-based stock units following the vesting of 2024 PSUs.

Summary

• Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences Inc. (CSTL), reported an acquisition of securities.
• Acquired 9,207 shares of Common Stock on January 12, 2026, at a price of $0.
• These shares represent 50% of the Performance-Based Stock Units (PSUs) granted on March 4, 2024, which vested due to the satisfaction of certain performance criteria certified by the board of directors.
• Following this transaction, Juvenal beneficially owns 96,032 shares of Common Stock.
• Also acquired 9,207 Performance-Based Stock Units (PSUs) on January 12, 2026, at a price of $0.
• These PSUs represent the remaining 50% of the 2024 PSUs, which will vest subject to the achievement of certain future milestones.
• Each PSU represents the right to receive one share of the Issuer's Common Stock.

Sentiment

Score: 7

Explanation: The vesting of performance-based stock units indicates the company met its performance targets, which is generally a positive sign for investors and aligns management incentives.

Positives

• 50% of the 2024 Performance-Based Stock Units (PSUs) vested, indicating the company met specific performance criteria as certified by the board of directors.
• The Chief Commercial Officer's beneficial ownership of common stock increased to 96,032 shares, further aligning management interests with shareholders.

Future Outlook

The remaining 50% of the 2024 Performance-Based Stock Units (9,207 units) are subject to future vesting upon the achievement of certain milestones.

Industry Context

This Form 4 filing details an insider transaction related to executive compensation, specifically the vesting of performance-based stock units. Such transactions are common across industries as a mechanism to align executive incentives with company performance and shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive, as management's interests are further aligned with shareholders through increased equity ownership, and the vesting indicates performance targets were met.
• Employees: The vesting of PSUs for a key executive could signal a positive internal environment regarding performance achievement and the effectiveness of incentive programs.

Next Steps

• Vesting of the remaining 50% of 2024 Performance-Based Stock Units upon the achievement of certain future milestones.

Key Dates

Recommendation

The filing reports a routine insider transaction related to the vesting of performance-based stock units, indicating the company met certain performance criteria. While positive, it does not present new fundamental information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate for existing investors. New investors would need to conduct further due diligence.

Keywords

Castle Biosciences, CSTL, Form 4, insider transaction, stock acquisition, performance-based stock units, CCO, Tobin W. Juvenal